CNTX
Context Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.24
−2.30%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -26.2%
- EBIT
- -27.2%
- EPS
- -14.6%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -20.1%
- EPS
- +14.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -35.2%
- EBIT
- -32.7%
- Net income
- -35.2%
- EPS
- +17.4%
- Free cash flow
- +9.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026